Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-Boost is a proprietary cell therapy platform developed by Sakura Bio designed to enhance the therapeutic potential of immune cells, including T cells and natural killer (NK) cells. The technology focuses on reprogramming these cells to improve their potency, persistence, and resilience within the immunosuppressive tumor microenvironment (TME). T-Boost is engineered to be compatible with various cell therapy modalities such as CAR-T, TCR-T, CAR-NK, and Tumor-Infiltrating Lymphocytes (TILs). By optimizing the metabolic and functional state of the cells, the platform aims to overcome common limitations in treating both solid and hematologic malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on T-Boost.